A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Clinical trial NCT05645107 · RECRUITING
Trial details
- NCT number
- NCT05645107
- Sponsor
- Grifols Therapeutics LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-26
- Primary completion
- 2029-08-01
- Enrollment
- 386
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.